Understanding how certain natural compounds can help reduce inflammation in sepsis.
TRPV1-dependent neuro-immune modulation and regulation of endogenous acyl-dopamines in sepsis and acute inflammation
This study is looking at how two natural compounds, OLDA and NADA, might help reduce inflammation and improve recovery in people with sepsis, by testing them in animal models to see how they affect the immune response and lung health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11092879 on NIH RePORTER |
What this research studies
This research investigates the role of two natural compounds, N-oleoyl dopamine (OLDA) and N-arachidonoyl dopamine (NADA), in modulating the immune response during sepsis. By studying their effects in animal models, the researchers aim to understand how these compounds can reduce inflammation and improve outcomes in sepsis. The approach includes administering these compounds and measuring their impact on inflammatory markers and lung injury. The ultimate goal is to uncover new therapeutic strategies for managing sepsis and acute inflammation.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults over 21 years old who are experiencing sepsis or acute inflammatory conditions.
Not a fit: Patients with chronic inflammatory diseases or those who are not experiencing acute inflammation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve recovery and outcomes for patients suffering from sepsis.
How similar studies have performed: Previous research has shown promising results with similar approaches in modulating inflammation, suggesting potential for success in this study.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Hellman, Judith — University of California, San Francisco
- Study coordinator: Hellman, Judith
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.